340B Drug Pricing Program
The Health Resources and Services Administration should abandon its consideration of a 340B rebate model pilot program because “a rebate mechanism of any kind is flawed in both conception and design,” the AHA told the agency today. Responding to a request for information, the AHA shared…
AHA Comments on 340B Rebate Model RFI.
The AHA responds to the Health Resources and Services Administration’s (HRSA) Request for Information regarding a potential 340B Rebate Model Pilot Program.
AHA responds to Washington Post editorial on 340B program.
AHA Seeks En Banc review of 4th Circuit 340B ruling.
The AHA and others April 17 filed an amicus brief requesting the U.S. Court of Appeals for the 4th Circuit grant en banc review of a panel decision that invalidated West Virginia’s law protecting 340B contract pharmacy arrangements.
The U.S. Court of Appeals for the 5th Circuit today affirmed rulings by a Mississippi district court that rejected requests by Novartis and PhRMA to enjoin enforcement of the state’s law protecting 340B pricing for contract pharmacy arrangements.
Several states have enacted laws protecting 340B contract pharmacy arrangements by requiring drug manufacturers to honor discounted pricing at those locations to preserve patient access. Manufacturers have challenged these laws in courts nationwide. This webpage compiles decisions in those cases as…
The U.S. District Court for the District of Columbia March 31 vacated a Health Resources and Services Administration policy instituted in 2013 that restricted how certain 340B hospitals could make initial drug purchases.
The U.S. Court of Appeals for the 4th Circuit March 31 upheld a preliminary injunction issued by the U.S. District Court for the District of West Virginia blocking the state from enforcing S.B. 325, its law requiring drug companies to provide access to 340B drug discounts to purchases through…